Related Experiment Video
Updated: Jan 16, 2026

A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Response to pembrolizumab in a patient with xeroderma pigmentosum, metastatic cutaneous melanoma and multiple
Júlia C Martins1, Abna F S Vieira1, Olavo Feher1
1Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil.
Abstract:
Xeroderma pigmentosum (XP) is a rare genetic disorder associated with defective DNA repair, leading to extreme ultraviolet sensitivity and a significantly elevated risk of malignancies. This case report details a patient with XP and metastatic melanoma who achieved complete clinical remission with pembrolizumab, highlighting the potential efficacy of immune checkpoint inhibitors in tumours with high mutational burdens. These findings underscore a promising therapeutic avenue for this vulnerable population with limited treatment options.

